The FDA approved this test in 2016 for use in liquid biopsy to identify patients for first-line EGFR-targeted therapy (e.g., erlotinib, a tyrosine kinase inhibitor (TKI)) of metastatic NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.